A decision to pause further dosing of PledOx in the POLAR program has been taken by Pledpharma following interaction with the French regulatory agency ANSM and previously issued clinical hold in the US. The decision increases our uncertainty about the future of the POLAR program, the timelines for the studies, and it might lead to the need for further funding.